Eli Lilly and Company
Reyvow is a prescription medication that is used for the acute treatment of migraine attacks with or without aura in adults.
Eli Lilly and Company’s Reyvow is a 5-HT1F serotonin receptor agonist that binds with high affinity to the 5-HT1F receptor, which is thought to be a cause of migraines.
Common side effects can include dizziness, sleepiness, numbness, feeling tired and tinging.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs